Topic Merck

Companies Merck

Products Merck

Pyrodetect System: the Human(e) Alternative in Pyrogen Testing

A revolutionary test for the detection and quantification of pyrogens based on the monocyte activation test (MAT) more

ISOSLIDE® Reticulin control slides for histology

The ISOSLIDE® Reticulin Control Slides Box is a new product from Merck Millipore for the detection of reticulin fibers in histological tissue specimen more

More content, more convenience – New packaging sizes for Entellan® New, Schiff's reagent and OSTEOMOLL®

Merck Millipore offers new, user-friendly packaging sizes for its microscopy products Entellan® new, Schiff´s reagent and OSTEOMOLL® more

Software Merck

50.000 HPLC Columns and UHPLC Columns from one source

With the new HPLC Column Configurator you find the HPLC Column you are looking for. Compare Columns of over 20 manufacturers from Agilent to Waters more

Catalogues Merck

Merck Millipore provides all expertise on chromatography in one place

With almost 400 pages, the catalog contains detailed information on a total of around 4,000 Merck Millipore chromatography products more

Naturally pure – New brochure

Download our new brochure, “Naturally Pure” more

News Merck

• Q1/2012: Merck Total Revenues Increase 3.2% to € 2.6 Billion

  “Merck delivered a reasonable operating performance in the face of a difficult year-over-year comparison,” said Karl-Ludwig Kley, Chairman of the Executive Board of Merck. “During the first quarter, we kicked off our efficiency program and announced the first planned initiatives as part of this tran more

• Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit

  Merck announced results from an interim analysis of the Phase III clinical trial PETACC-81. The study investigated the potential clinical utility of Erbitux® (cetuximab) for the adjuvant treatment of stage III colon cancer after complete surgical removal of the primary tumor. The pre-specified inter more

• Merck Announces Merck Serono Implementation Plans for Its Efficiency Program in Switzerland

  Merck announced the efficiency measures it plans to take related to Merck Serono’s operations in Switzerland as part of the comprehensive transformation program announced by the company in February. Merck’s transformation program is focused on addressing unprecedented market shifts, increasing compe more

White papers Merck

• Altered Expression of Broad Range of Protease Genes in SH-SY5Y Neuroblastoma Cells after Bortezomib Exposure
  

  Neuroblastoma cell lines can be models for the responsiveness of neuroblastomas to chemotherapy-induced cell death as well as for the sensitivity of untransformed neuro-nal cells to toxic side-effects of chemotherapy. Both phenom-ena are relevant to neuroblastoma cells exposed to bortezomib, a proteasome inhibitor in clinical use. It has been shown previously that neuroblastoma cell lines are prone to undergo apoptosis when treated with bortezomib, but the precise molecular mechanism has not been revealed. In addition to this, peripheral neuropathy is the main side effect of chemotherapy that includes bortezomib more

Publications Merck

• [News & Analysis] Drug Discovery: New Institute Aims to Help Academics Make Medicines

  This week, Merck launched a new nonprofit research institute to help academics turn their basic biology insights into drug compounds ready for human tests. more

• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  Abstract We recently reviewed the status of peptide and non‐peptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT) (1). In this review we update the status of peptides and non‐peptides as (a) research tools and more

• [News of the Week] Around the World

  In science news around the world this week, FDA's decision on an emergency contraceptive has been overruled, controversial changes to forest law have been passed in the Brazilian Senate, climate negotiators have agreed to pursue a new treaty, Merck has committed $1.5 billion to build in Beijing, the more

Market studies Merck

• Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Vaginitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Vaginitis Infection Therapeutics market. The report identi more

• Healthcare, Regulatory and Reimbursement Landscape - US

  Introduction Industry analysis specialist GlobalData, has released its new report, “Healthcare, Regulatory and Reimbursement Landscape - US”. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of the US. It identifies the key t more

• Brazil Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Brazil remains the most attractive emerging pharmaceutical market in the Americas due to its large population, strong consumer demand, increasing urbanisation and comparatively good drug regulatory environment. Many multinational pharmaceutical companies reported double digital growth duri more

Websites Merck